[The early and late sequelae of the toxic action on the liver of a platinum antitumor preparation].
It has been shown in experiments on Wistar rats that the antitumor agent platidiam given in MTD causes increased activity of alanine and aspartate aminotransferases (up to the 15th day after administration), persisting changes in the beta- and pre-beta-lipoprotein level, and intensified LPO in the blood (up to 3-months). Acute toxic hepatitis induced in rats by injection of CCl4 1, 3, and 6 months after a single platidiam administration is characterized by hepatic disorders which are more pronounced than those than those in intact animals with CCl4 hepatitis.
Vetoshkina
T V
TV
Dubskaia
T Iu
TIu
Gol'dberg
V E
VE
D000208:Acute Disease; D000410:Alanine Transaminase / Q000097:blood / Q000187:drug effects; D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001219:Aspartate Aminotransferases / Q000097:blood / Q000187:drug effects; D002252:Carbon Tetrachloride Poisoning / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood; D002945:Cisplatin / Q000633:toxicity*; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects; D008079:Lipoproteins, VLDL / Q000097:blood / Q000187:drug effects; D008099:Liver / Q000187:drug effects*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000970:Antineoplastic Agents; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D008315:Malondialdehyde; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D002945:Cisplatin